Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Controlled, Randomized, Multicenter, Dose Escalation Study Evaluating the Safety and Efficacy of StrataGraft® Skin Tissue in Promoting the Healing of the Deep Partial-Thickness Component of Complex Skin Defects as an Alternative to Autografting

NCT01437852 is registered in ClinicalTrials.gov with Stratatech, a Mallinckrodt Company as lead sponsor.

NCT NCT01437852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01437852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Controlled, Randomized, Multicenter, Dose Escalation Study Evaluating the Safety and Efficacy of StrataGraft® Skin Tissue in Promoting the Healing of the Deep Partial-Thickness Component of Complex Skin Defects as an Alternative to Autografting
Lead sponsor
Stratatech, a Mallinckrodt Company
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2011
Completion date
October 31, 2014
Enrollment
30 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

burns, skin wound, trauma-related wound